Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) is a clinical-stage biotechnology company developing bacteriophage therapies for antibiotic-resistant and difficult-to-treat bacterial infections. Its pathogen-specific candidates are designed to target bacteria while sparing the normal human microbiome, and are being… From the company’s description.
Over the twelve months to Jun 30, 2026, Armata Pharmaceuticals, Inc. reported revenue of $5.54M, down 19.3% from a year earlier, and a net loss of $192.18M. Its operating margin was −734.2%, and operations used $25.42M in cash. In fiscal 2025, it reported revenue of $4.90M, down 5.2% from fiscal 2024, and a net loss of $173.80M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Armata Pharmaceuticals, Inc. does
In the company’s own words
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) is a clinical-stage biotechnology company developing bacteriophage therapies for antibiotic-resistant and difficult-to-treat bacterial infections. Its pathogen-specific candidates are designed to target bacteria while sparing the normal human microbiome, and are being studied as alternatives or adjuncts to antibiotics. AP-PA02 is an inhaled candidate for chronic lung infections caused by Pseudomonas aeruginosa, including infections associated with non-cystic fibrosis bronchiectasis and cystic fibrosis; AP-SA02 is an intravenous candidate for complicated Staphylococcus aureus bacteremia. The company is also exploring AP-PA03 for acute P. aeruginosa infections, including ventilator-associated pneumonia, and potential AP-SA02 development for joint and wound infections. Armata combines phage discovery and characterization with host-engineered manufacturing capabilities, and its programs are supported in part by collaborations and awards from the Cystic Fibrosis Foundation and the U.S. Department of Defense. Its website is https://www.armatapharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- LOS ANGELES, CA
- Fiscal year end
- December
- CIK
- 921114
- SIC
- 2836
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Armata Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Armata Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Armata Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Armata Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Armata Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”